Skip to main content
Clinical Trials/IRCT20200828048551N1
IRCT20200828048551N1CompletedPhase 2

Efficasy and safety of intrathecal injection of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS)

Ahvaz University of Medical Sciences0 sites10 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
25 years to 70 years (—)
Sex
All

Inclusion Criteria

  • Patients diagnosed as definite or probable ALS disease according to EL Escorial criteria
  • ALSFRS-R more than 26
  • FVC more than 40%
  • age 25-70 years
  • Time passed since onset of the symptoms till inclusion be 3 years or less

Exclusion Criteria

  • Any major systemic disease
  • Any coexisting neurodegenerative disease
  • No other major pathology in brain or spinal cord
  • pregnancy or lactation

Investigators

Similar Trials

Efficasy and safety of intrathecal... | Clinical Trial